DDInter1484 DDInter899
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Plicamycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Plicamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Plicamycin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan
Plicamycin may lead to a major life threatening interaction when taken with Regorafenib